敷脐透肠疗法联合人脐带间充质干细胞治疗肝硬化难治性腹水的效果.docVIP

敷脐透肠疗法联合人脐带间充质干细胞治疗肝硬化难治性腹水的效果 　　[摘要] 目的 观察敷脐透肠疗法联合人脐带间充质干细胞治疗肝硬化难治性腹水的临床效果。 方法 收集2015年9月～2016年2月在深圳市中医院住院治疗的肝硬化难治性腹水患者59例，采用随机数字表法将其分为实验组（29例）和对照组（30例）。根据患者的情况采用相应的基础治疗，同时实验组给予麝黄膏贴敷神阙穴、结肠透析方灌肠联合人脐带间充质干细胞治疗，对照组给予麝黄膏贴敷神阙穴、结肠透析方灌肠治疗，疗程均为4周。观察比较两组患者的谷丙转氨酶（ALT）、谷草转氨酶（AST）、白蛋白（ALB）、总胆红素（TB）、凝血酶原时间（PT）、腹围、门静脉宽度（PVD）、平均门静脉血流量（QPV）、脾静脉宽度（SVD）、平均脾静脉血流量（QSV）。 结果 治疗前后实验组PVD、QPV、SVD、QSV均发生明显变化，差异均有高度统计学意义（P 0.05）。 结论 敷脐透肠联合人脐带间充质干细胞疗法可以显著改善肝硬化难治性腹水患者肝脏的合成功能和门、脾静脉血流动力学 [关键词] 肝硬化难治性腹水；人脐带间充质干细胞；敷脐透肠；临床疗效 [中图分类号] R657.31 [文献标识码] A [文章编号] 1673-7210（2016）08（a）-0004-04 [Abstract] Objective To observe the clinical effects of navel-applied plaster and colon dialysis combined with Huc-MSCs to treat refractory ascites of cirrhosis. Methods Fifty-nine patients with refractory ascites from September 2015 to February 2016 in Chinese Medicine Hospital of Shenzhen were collected， and they were divided into trail group （29 cases） and control group （30 cases） by random number table and. Patients of the two groups were treated with same basic treatments. The trail group was treated with Shehuang navel-applied plaster， colon dialysis and Huc-MSCs. Control group was treated with Shehuang navel-applied plaster and colon dialysis. Two groups were treated for 4 weeks. ALT， AST， ALB， TB， PT， PVD， QPV， SVD， QSV and abdominal perimeter before and after treatment were observed and statistic analyzed. Results Before and after treatment， PVD， QPV， SVD， QSV of the trail group had statistically significant differences（P 0.05）. Conclusion Therapy of Navel-applied plaster and colon dialysis combined with Huc-MSCs can improve synthetic function of liver and haemodynamics of splenic vein and portal vein for refractory ascites of cirrhosis. [Key words] Refractory ascites of cirrhosis； Human umbilical cord-derived mesenchymal stem cells； Navel-applied plaster and colon dialysis； Clinical effects 腹水是肝硬化患者临床常见的并发症，也是肝硬化的转折点，标志着肝硬化的进展和肝脏功能进入失代偿状态。代偿期肝硬化患者10年内50%发生腹水，肝硬化腹水患者1年内15%发生死亡，5年内44%发生死亡[1]；若肝硬